Try our mobile app

Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study

Published: 2021-09-16 11:00:00 ET
<<<  go to GILD company page

– TNBC Severely Impacts Patient Health-Related Quality of Life, with Poorer Outcomes for Those with Metastatic Disease vs. Other Breast Cancer Subtypes –

– Trodelvy Is First Treatment to Improve Survival in Metastatic TNBC –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In addition to the previously reported overall survival benefit observed with Trodelvy compared with chemotherapy chosen by patients’ physicians (11.8 months vs. 6.9 months; HR: 0.51; 95% CI: 0.41-0.62; p